DE69432076T2 - Neue pharmazeutische formulierungen - Google Patents

Neue pharmazeutische formulierungen

Info

Publication number
DE69432076T2
DE69432076T2 DE69432076T DE69432076T DE69432076T2 DE 69432076 T2 DE69432076 T2 DE 69432076T2 DE 69432076 T DE69432076 T DE 69432076T DE 69432076 T DE69432076 T DE 69432076T DE 69432076 T2 DE69432076 T2 DE 69432076T2
Authority
DE
Germany
Prior art keywords
pct
pharmaceutical formulations
new pharmaceutical
formulation
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432076T
Other languages
English (en)
Other versions
DE69432076D1 (de
Inventor
Inga Siv Bengtsson
Kurt Ingmar Loevgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69432076(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69432076D1 publication Critical patent/DE69432076D1/de
Publication of DE69432076T2 publication Critical patent/DE69432076T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69432076T 1993-07-09 1994-07-08 Neue pharmazeutische formulierungen Expired - Lifetime DE69432076T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation
PCT/SE1994/000681 WO1995001783A1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation

Publications (2)

Publication Number Publication Date
DE69432076D1 DE69432076D1 (de) 2003-03-06
DE69432076T2 true DE69432076T2 (de) 2003-10-16

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432076T Expired - Lifetime DE69432076T2 (de) 1993-07-09 1994-07-08 Neue pharmazeutische formulierungen

Country Status (40)

Country Link
US (1) US5690960A (de)
EP (1) EP0706378B1 (de)
JP (1) JP3665334B2 (de)
KR (1) KR100350203B1 (de)
CN (1) CN1126946A (de)
AT (1) ATE231719T1 (de)
AU (1) AU681686B2 (de)
BR (1) BR9406941A (de)
CA (1) CA2166483C (de)
CZ (1) CZ290323B6 (de)
DE (1) DE69432076T2 (de)
DK (1) DK0706378T3 (de)
DZ (1) DZ1794A1 (de)
EE (1) EE03148B1 (de)
EG (1) EG22373A (de)
ES (1) ES2191682T3 (de)
FI (1) FI114008B (de)
HK (1) HK1008299A1 (de)
HR (1) HRP940386B1 (de)
HU (1) HU226779B1 (de)
IL (1) IL110189A0 (de)
IS (1) IS2034B (de)
LV (1) LV13140B (de)
MA (1) MA23258A1 (de)
MX (1) MX9405219A (de)
MY (1) MY128809A (de)
NO (1) NO315146B1 (de)
NZ (1) NZ268694A (de)
PL (1) PL175210B1 (de)
RU (1) RU2138254C9 (de)
SA (1) SA94150057B1 (de)
SE (1) SE9302395D0 (de)
SG (1) SG52365A1 (de)
SI (1) SI0706378T1 (de)
SK (1) SK281105B6 (de)
TN (1) TNSN94078A1 (de)
UA (1) UA43342C2 (de)
WO (1) WO1995001783A1 (de)
YU (1) YU49199B (de)
ZA (1) ZA944934B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP2001524131A (ja) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク 安定な経口医薬品剤形
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP1004305B1 (de) * 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilisierte zusammenstellungen die benzimidazole enthalten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
CN100503598C (zh) * 1998-11-18 2009-06-24 阿斯特拉曾尼卡有限公司 改进的化学方法和药物制剂
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
PL360916A1 (en) * 1999-03-29 2004-09-20 Wyeth Coating system
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2387746C (en) 1999-10-20 2010-06-29 Koji Ukai Methods for stabilizing benzimidazole-based compounds
US20030212274A1 (en) * 2000-05-15 2003-11-13 Bakthavathsalan Vijayaraghavan Novel amorphous form of omeprazole salts
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
ES2426723T3 (es) 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
KR20050008452A (ko) * 2002-03-08 2005-01-21 바쿠레시 마파탈 카마르 결핵의 치료방법
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
CA2494716A1 (en) * 2002-08-02 2004-02-19 Ratiopharm Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) * 2003-03-28 2004-09-29 Acme Drugs S R L Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (de) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP1845982A2 (de) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Durch ein nichtwässriges schichtungsverfahren hergestellte stabile orale benzimidaziol-zusammensetzungen
JP5124267B2 (ja) 2005-02-25 2013-01-23 武田薬品工業株式会社 顆粒の製造方法
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2068837A2 (de) * 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Pharmazeutische zusammensetzungen in granulatform
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP2293782B1 (de) * 2008-05-06 2015-08-12 Dexcel Pharma Technologies Ltd. Stabile benzimidazolformulierung
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2344139A1 (de) 2008-09-09 2011-07-20 AstraZeneca AB Verfahren zur abgabe einer pharmazeutischen zusammensetzung an einen patienten, der diese benötigt
KR101699912B1 (ko) * 2009-01-09 2017-01-25 포워드 파마 에이/에스 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
EP2445499A4 (de) 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
EP2345408A3 (de) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Säurelabile Arzneimittelformulierungen
EP2720605B1 (de) 2011-06-14 2020-03-11 Gravitas Medical Inc. Vorrichtung zur durchführung einer medizinischen versorgung auf basis einer erkannten magenfunktion
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
US20230058473A1 (en) 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN113350313B (zh) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 一种艾司奥美拉唑镁延释制剂及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation

Also Published As

Publication number Publication date
BR9406941A (pt) 1996-09-10
AU7198294A (en) 1995-02-06
NZ268694A (en) 1997-05-26
UA43342C2 (uk) 2001-12-17
EE03148B1 (et) 1999-02-15
EP0706378B1 (de) 2003-01-29
MA23258A1 (fr) 1995-04-01
EG22373A (en) 2002-12-31
FI960102A0 (fi) 1996-01-09
SK2196A3 (en) 1997-04-09
CA2166483C (en) 1997-09-16
ES2191682T3 (es) 2003-09-16
JPH08512316A (ja) 1996-12-24
NO960067D0 (no) 1996-01-05
NO315146B1 (no) 2003-07-21
EP0706378A1 (de) 1996-04-17
CZ290323B6 (cs) 2002-07-17
SG52365A1 (en) 1998-09-28
WO1995001783A1 (en) 1995-01-19
ATE231719T1 (de) 2003-02-15
RU2138254C1 (ru) 1999-09-27
SA94150057B1 (ar) 2006-10-03
SE9302395D0 (sv) 1993-07-09
HUT75306A (en) 1997-05-28
MY128809A (en) 2007-02-28
HRP940386A2 (en) 1997-02-28
YU43794A (sh) 1997-07-31
HU9503874D0 (en) 1996-02-28
IS2034B (is) 2005-08-15
IL110189A0 (en) 1994-10-21
IS4187A (is) 1995-01-10
HK1008299A1 (en) 1999-05-07
DK0706378T3 (da) 2003-05-05
NO960067L (no) 1996-01-05
HRP940386B1 (en) 2003-10-31
SI0706378T1 (en) 2003-06-30
ZA944934B (en) 1995-02-20
MX9405219A (es) 1995-01-31
DE69432076D1 (de) 2003-03-06
JP3665334B2 (ja) 2005-06-29
RU2138254C9 (ru) 2009-09-27
CZ7096A3 (en) 1996-06-12
PL312441A1 (en) 1996-04-29
TNSN94078A1 (fr) 1995-04-25
DZ1794A1 (fr) 2002-02-17
YU49199B (sh) 2004-09-03
LV13140B (en) 2004-08-20
CA2166483A1 (en) 1995-01-19
SK281105B6 (sk) 2000-12-11
PL175210B1 (pl) 1998-11-30
KR100350203B1 (ko) 2002-12-28
FI114008B (fi) 2004-07-30
US5690960A (en) 1997-11-25
AU681686B2 (en) 1997-09-04
FI960102A (fi) 1996-01-09
HU226779B1 (en) 2009-10-28
CN1126946A (zh) 1996-07-17

Similar Documents

Publication Publication Date Title
ATE231719T1 (de) Neue pharmazeutische formulierungen
MY112915A (en) Multiple unit tableted dosage form 1
GEP20012375B (en) Isothiazolones, Pharmaceutical Composition on Their Basis and Method for Obtaining the Same
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
NO963634D0 (no) Antihostepreparat inneholdende et antihostemiddel og benzydamin
DE69104083D1 (de) Neue Antiulcus-Substanz.
HRP20000781B1 (en) Effervescent preparations
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
JO1821B1 (en) New pharmaceutical product

Legal Events

Date Code Title Description
8364 No opposition during term of opposition